All Stories

Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences drug can hold its own against FDA-approved products Seysara and doxycycline.

Jun 4, 2025 - 12:15
 0
Ascletis scores phase 3 win for daily acne pill, prepares push to Chinese regulators
Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences drug can hold its own against FDA-approved products Seysara and doxycycline.
Read More

Tags:

Previous Article

Unstoppable Momentum in the Quality Management Software (Qms) Market

Next Article

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab,...

Related Posts

Eli Lilly lands next-gen pain asset in SiteOne Therapeutics acquisition worth up to $1B

Eli Lilly lands next-gen pain asset in SiteOne Therapeu...

May 27, 2025  0

Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off staff

Prime Medicine CEO exits as biotech shelves sole clinic...

May 19, 2025  0

Allogene lays off 28% of staff to extend runway amid delays to CAR-T updates

Allogene lays off 28% of staff to extend runway amid de...

May 14, 2025  0